Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Pathogenesis and Immunity

Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1

Aran F. Labrijn, Pascal Poignard, Aarti Raja, Michael B. Zwick, Karla Delgado, Michael Franti, James Binley, Veronique Vivona, Christoph Grundner, Chih-Chin Huang, Miro Venturi, Christos J. Petropoulos, Terri Wrin, Dimiter S. Dimitrov, James Robinson, Peter D. Kwong, Richard T. Wyatt, Joseph Sodroski, Dennis R. Burton
Aran F. Labrijn
1Department of Immunology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pascal Poignard
1Department of Immunology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aarti Raja
2Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael B. Zwick
1Department of Immunology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karla Delgado
1Department of Immunology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Franti
1Department of Immunology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Binley
1Department of Immunology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Veronique Vivona
1Department of Immunology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Grundner
2Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chih-Chin Huang
3Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miro Venturi
3Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christos J. Petropoulos
4ViroLogic, Inc., South San Francisco, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Terri Wrin
4ViroLogic, Inc., South San Francisco, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dimiter S. Dimitrov
5Laboratory of Experimental and Computational Biology, National Cancer Institute-Frederick, National Institute of Health, Frederick, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Robinson
6Department of Pediatrics, Tulane University Medical Center, New Orleans, Louisiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter D. Kwong
3Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard T. Wyatt
2Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute
3Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Sodroski
2Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute
7Department of Pathology, Division of AIDS, Harvard Medical School
8Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dennis R. Burton
1Department of Immunology
9Department of Molecular Biology, The Scripps Research Institute, La Jolla
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: burton@scripps.edu
DOI: 10.1128/JVI.77.19.10557-10565.2003
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIG. 1.
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Neutralization of HIV-1JR-CSF by CD4i antibodies and antibody fragments. Neutralization titers of whole antibodies (•), Fab fragments (○), and scFv fragments (▪) to HIV-1JR-CSF were determined in a pseudotyped luciferase-based neutralization assay with U87.CD4.CCR5 cells. Datum points are the means of triplicates ± the standard error of the mean (SEM).

  • FIG. 2.
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    Binding curves of CD4i antibodies and antibody fragments to monomeric gp120JR-CSF as determined by ELISA. Titers of whole antibodies (A) and Fab fragments (B) to gp120JR-CSF were determined in the presence (solid symbols) or absence (open symbols) of saturating amounts of sCD4. Symbols: circles, 17b; squares, 48d; triangles, X5. Datum points are the means of at least two separate experiments ± the standard deviation.

  • FIG. 3.
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    Neutralization of dualtropic HIV-1 by MAb X5 whole IgG and antibody fragments. Titers of whole antibody (•), Fab fragment (○) and scFv fragment (▪) to HIV-189.6 (A and B) and HIV-1JR-CSF/IR (C and D) were determined in a pseudotyped luciferase-based neutralization assay with U87.CD4 cells expressing either CCR5 (A and C) or CXCR4 (B and D). Datum points are the means of triplicates ± the SEM.

  • FIG. 4.
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    Pre- and postattachment neutralization of HIV-1ADA and HIV-1ADAΔV1V2 by MAb 17b whole antibody and antibody fragments. Neutralization titers of whole antibody (•), Fab fragment (○), and scFv fragment (▪) to HIV-1ADA (A) and HIV-1ADAΔV1V2 (B and C) were determined in a pseudotyped luciferase-based neutralization assay with Cf2Th cells expressing CD4 and CCR5. In these settings pre- and postattachment neutralizations were measured simultaneously (A and B) by preincubating virus and antibody fragments at 37°C prior to addition to cells. (C) Postattachment neutralization was measured exclusively by preincubating virus and cells at 4°C, washing the cells, and adding antibody fragments before the temperature was increased to 37°C.

  • FIG. 5.
    • Open in new tab
    • Download powerpoint
    FIG. 5.

    Standard and postattachment neutralization of SOSJR-FL and WTJR-FL by CD4i whole antibodies and antibody fragments. Antibodies 17b (IgG [A] and scFv [B]), X5 (Fab [C] and scFv [D]), b12 (IgG [E]), and 2F5 (IgG [F]) were tested in pseudotyped luciferase-based neutralization assays, under standard assay conditions against WTJR-FL (▪) and SOSJR-FL, and in a postattachment format against SOSJR-FL (○). Datum points are the means of triplicates ± the SEM.

  • FIG. 6.
    • Open in new tab
    • Download powerpoint
    FIG. 6.

    Steric restrictions on CD4i antibody neutralization after CD4 attachment. (A) HIV-1 viral spike attached to cell surface CD4. The gp120 trimer (brown) (27) is shown with the threefold axis oriented perpendicular to the target cell surface. Cα worm representations of gp120 and four-domain CD4 are shown in brown and yellow, respectively. N-linked carbohydrate on gp120 is shown in blue. The flexibility between the second and third extracellular CD4 domains allows the observed angle between the membrane-distal (D1D2) and membrane-proximal (D3D4) domains to vary by up to 10° (distinct crystal structure conformations are shown in red and yellow) (58). The distance between the membrane-proximal portion of gp120 and the bottom of the crystallographically ordered CD4 is ∼45 Å. Nine amino acids (shown in gray) occur between the last ordered crystallographic residue (position 363) and the transmembrane domain (starting at position 373), potentially increasing the gp120-target cell membrane distance by 20 Å. There is considerable uncertainty in the degree of flexibility between the second and third extracellular domains of CD4. If the interdomain rotation is increased by 35° (gray), the gp120-target cell membrane distance would increase by an additional 20 Å, resulting in a total gp120-transmembrane distance of up to 85 Å. (B) Dimensions of Fv, Fab, and IgG portions of 17b interacting with gp120. Both gp120 (brown) and antibody fragments (purple) are shown in the Cα worm representation. The gp120 molecule is depicted in precisely the same orientation as the front left protomer in panel A, with the 17b portion oriented by superimposing the X-ray structure (pdb accession number 1G9 M [25]) of the gp120 ternary complex with D1D2 and 17b Fab complex. The length of the 17b Fv along the trimer threefold axis is ∼40 Å, and the length of the Fab is ∼60 Å, with the dimensions measured for the distance between the target membrane-proximal portions of gp120 and 17b. For IgGs, considerable flexibility is found in the hinge region connecting Fab and Fc portions of the IgG. Superimposing the crystal structure of a full-length human antibody (45) onto 17b gives dimensions of 115 Å (shown here) and 140 Å (not shown) for the two alternative Fab superpositions. The figures were generated with GRASP (34).

Tables

  • Figures
  • TABLE 1.

    Neutralization of HIV-1 by CD4i antibodies and antibody fragments (standard neutralization assay A)

    MAbFormatNeutralization (IC50 [nM])a of HIV-1 isolate
    JR-CSF R5JRFL R5ADA R589.6 X4HxB2 X4
    X5IgG1,7991,950>2,000 (14)3478.1
    Fab458955>2,000 (33)75974
    scFv22411544719116
    17bIgG>2,000 (22)>2,000 (20)>2,000 (32)18921
    Fab9122881,77824243
    scFv15833144712261
    48dIgG>2,000 (41)NT1,3804578.7
    Fab1,698NT>2,000 (32)>2,000 (36)39
    • ↵ a Neutralization was assessed on U87.CD4 cells expressing either the CCR5 (R5) or the CXCR4 (X4) coreceptor. The neutralization of the dual-tropic isolate 89.6 was studied on U87.CD4 cells expressing CXCR4. Where 50% neutralization was not achieved, the percent inhibition at the highest antibody concentration is given in parentheses. IC50, concentration of antibody causing a 50% reduction in viral infection; NT, not tested.

  • TABLE 2.

    Neutralization of HIV-1 by CD4i antibodies and antibody fragments (standard neutralization assay B)a

    MAbFormatNeutralization (IC50 [nM]) of HIV-1 isolate
    SF162 R592HT594 R5X4JR-CSF R5JR-FL R5ADA R5HxB2 X4A-MLVb
    X5IgG0.2267>333 (16)>333 (15)>333 (0)1.8>333
    Fab2.8283>1,000 (25)>1,000 (13)>1,000 (15)35>1,000
    scFv1.71296331,0776371.2>2,000
    17bIgG3.1>333 (21)>333 (0)>333 (0)>333 (0)15>333
    scFv3.911736957329445>1,160
    b12IgG0.462.17.30.76180.07>333
    b6IgG0.53>333 (42)>333 (0)>333 (0)>333 (0)0.38>333
    • ↵ a Neutralization was assessed on U87.CD4 cells expressing both CCR5 and CXCR4 coreceptors. Coreceptor tropism of the viral isolates is indicated (R5, X4, or R5X4). Where 50% neutralization was not achieved, the percent inhibition at the highest antibody concentration is given in parentheses. IC50, concentration of antibody causing a 50% reduction in viral infection.

    • ↵ b As a negative control, pseudovirions expressing the A-MLV env gene were included.

PreviousNext
Back to top
Download PDF
Citation Tools
Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1
Aran F. Labrijn, Pascal Poignard, Aarti Raja, Michael B. Zwick, Karla Delgado, Michael Franti, James Binley, Veronique Vivona, Christoph Grundner, Chih-Chin Huang, Miro Venturi, Christos J. Petropoulos, Terri Wrin, Dimiter S. Dimitrov, James Robinson, Peter D. Kwong, Richard T. Wyatt, Joseph Sodroski, Dennis R. Burton
Journal of Virology Sep 2003, 77 (19) 10557-10565; DOI: 10.1128/JVI.77.19.10557-10565.2003

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1
Aran F. Labrijn, Pascal Poignard, Aarti Raja, Michael B. Zwick, Karla Delgado, Michael Franti, James Binley, Veronique Vivona, Christoph Grundner, Chih-Chin Huang, Miro Venturi, Christos J. Petropoulos, Terri Wrin, Dimiter S. Dimitrov, James Robinson, Peter D. Kwong, Richard T. Wyatt, Joseph Sodroski, Dennis R. Burton
Journal of Virology Sep 2003, 77 (19) 10557-10565; DOI: 10.1128/JVI.77.19.10557-10565.2003
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

CD4 Antigens
HIV Antibodies
HIV Envelope Protein gp120
HIV-1

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514